Zosano Pharma Corporation (NASDAQ:ZSAN) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

Zosano Pharma Corporation (NASDAQ:ZSAN) opened at 0.84 on Friday. The company has a 50-day moving average of $1.06 and a 200-day moving average of $1.54. Zosano Pharma Corporation has a 12 month low of $0.45 and a 12 month high of $3.54. The stock’s market cap is $32.95 million.

Zosano Pharma Corporation (NASDAQ:ZSAN) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. During the same quarter last year, the company posted ($0.54) EPS. On average, equities analysts forecast that Zosano Pharma Corporation will post ($0.79) EPS for the current fiscal year.

WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/01/zosano-pharma-corporation-zsan-lifted-to-sell-at-valuengine.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new position in Zosano Pharma Corporation during the first quarter valued at approximately $950,000. Victory Capital Management Inc. acquired a new position in Zosano Pharma Corporation during the first quarter valued at approximately $449,000. Granite Point Capital Management L.P. acquired a new position in Zosano Pharma Corporation during the first quarter valued at approximately $285,000. Endurant Capital Management LP acquired a new position in Zosano Pharma Corporation during the first quarter valued at approximately $1,135,000. Finally, Nexthera Capital LP acquired a new position in Zosano Pharma Corporation during the first quarter valued at approximately $950,000. Institutional investors and hedge funds own 22.66% of the company’s stock.

About Zosano Pharma Corporation

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Receive News & Stock Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related stocks with our FREE daily email newsletter.